pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Pulmonary%20arterial%20hypertension Management

Monitoring

  • A sustained response is considered when treated patients continue in World Health Organization (WHO) functional class I or II with near-normal hemodynamics after several month of treatment

Prevention

General Care

Maintenance of Intravascular Volume

  • Near-normal intravascular volume is important in the long-term management of idiopathic pulmonary arterial hypertension (IPAH)
    • Sodium-restricted (<2400 mg/day) diet, fluid restriction & judicious use of diuretics reduces volume overload in patients with pulmonary hypertension (PH) & right ventricular hypertension
  • Monitor renal function & blood biochemistry in patients to avoid hypokalemia & the effects of decreased intravascular volume leading to pre-renal failure

Hemoglobin (Hb) Levels

  • PAH patients are extremely sensitive to decreases in hemoglobin (Hb) levels
    • Anemias should be promptly treated
  • Phlebotomies should be done if hematocrit (Hct) >65% in symptomatic patients (headache, poor concentration)

Concomitant Medications

  • Avoid drugs that interfere with oral anticoagulants or increase risk of GI bleeding
  • Empiric use of angiotensin-converting enzyme (ACE) inhibitors or beta-blockers should be discouraged as this may result in hypotension & right heart failure

Prevention of Infection

  • Due to potentially devastating effects of respiratory tract infection in patients with pulmonary hypertension, immunization with influenza & pneumococcal vaccine is warranted
  • Respiratory tract infection should be treated aggressively

Follow Up

  • Ensure compliance of patients to their follow-up schedule, especially those belonging to WHO FC I
  • Follow-up visit at 3-6 months & 6-12 months after initial follow-up is advised
  • Baseline measurements of the following should be established during the initial follow-up, & in all patients showing signs of worsening clinical status:
    • Medical history
    • WHO-FC
    • ECG
    • 6MWT/Brog dyspnea score
    • Basic blood exams (eg CBC, INR, serum creatinine, sodium, potassium, AST/ALT, bilirubin, BNP/NT-proBNP)
    • CPET
    • Echocardiography
    • Specific laboratory tests (eg TSH, troponin, uric acid, iron levels)
    • Blood gas analysis
    • Right heart catheterization (RHC)
  • Patient’s medical history and functional class should be assessed using ECG, 6MWT/Borg dyspnea score & basic laboratory exams (eg CBC, INR, serum creatinine, sodium, potassium, AST/ALT, bilirubin, BNP/NT-proBNP levels) every follow-up visit of 3-6 months
  • CPET, echocardiography, specific laboratory tests (eg TSH, troponin, uric acid, iron levels), blood gas analysis, & RHC should be added at 6-12 months follow-up visit
  • At 3-6 months after every treatment adjustment, repeat evaluation of the patient’s complete medical history, functional class, ECG, 6MWT, echocardiography, basic blood tests, blood gas analysis & RHC are recommended
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.